Initiator Pharma reported no revenue and a reduced net loss in Q3 2024, advanced pudafensine for ED and FSD, and strengthened its patent portfolio. Equity improved due to share issues and receivable conversion, while the company remains focused on cost control and business development.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.